Collaborative for Research on Outcomes and -Metrics, Silver Spring, MD, USA.
Departments of Neurology and Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC, USA.
PM R. 2021 Jul;13(7):695-706. doi: 10.1002/pmrj.12470. Epub 2020 Nov 10.
To test the effectiveness of intravesical Lactobacillus rhamnosus GG (LGG) to reduce the burden of urinary symptoms for individuals with spinal cord injury and disease (SCI/D) with neurogenic lower urinary tract dysfunction (NLUTD) who manage their bladders with intermittent catheterization (IC).
A three-phase study (6 months each in baseline, intervention, and washout). Participants self-managed following the Self-Management Protocol using Probiotics (SMP-Pro), completing the online Urinary Symptom Questionnaire for Neurogenic Bladder-IC version (USQNB-IC) weekly.
Nationwide (United States).
Ninety-six adults and seven children with SCI/D.
In response to one or both of the SMP-Pro trigger urinary symptoms, "cloudier" or "foul smelling" urine, participants self-administered using a clean urinary catheter an LGG+ Normal Saline instillate once or twice in a 30-hour period.
Change in USQNB-IC burden was adjusted individually according to the previous phase for four symptom types. Adjusted changes in burden between the intervention and washout phases were analyzed using one-sample t-tests. Holm correction was applied for the four types of symptoms: A, clinically actionable; B1, bladder function; B2, urine quality; and C, other.
During the intervention phase, participants met SMP-Pro instillation criteria 3.83 times on average (range 1-20). An average of 5.6 doses of LGG were instilled. For those who instilled at least once, burdens of type A and B2 symptoms were significantly improved at washout (both adjusted P < .05).
Self-instilled LGG seemed to improve "clinically actionable" (A) and "urine quality" (B2) symptom burden. No changes were observed for those who did not instill. This first-in-human clinical trial supports ongoing research of intravesical LGG, and the SMP-Pro for urinary symptoms.
测试膀胱内给予鼠李糖乳杆菌 GG(LGG)对伴有神经源性下尿路功能障碍(NLUTD)的脊髓损伤和疾病(SCI/D)患者减轻间歇性导尿(IC)管理下的尿路症状负担的效果。
三阶段研究(基线、干预和洗脱期各 6 个月)。参与者按照益生菌自我管理方案(SMP-Pro)自我管理,每周在线填写神经源性膀胱-IC 版尿症状问卷(USQNB-IC)。
全国范围(美国)。
96 名成人和 7 名儿童 SCI/D。
针对 SMP-Pro 触发的一个或两个尿路症状(“浑浊”或“有异味”的尿液),参与者使用清洁的导尿管在 30 小时内自行给予 LGG+生理盐水灌洗一次或两次。
根据前一阶段,针对四种症状类型,单独调整 USQNB-IC 负担的变化。使用单样本 t 检验分析干预和洗脱阶段之间的调整后负担变化。对四种症状类型(A,具有临床可操作性;B1,膀胱功能;B2,尿液质量;和 C,其他)应用 Holm 校正。
在干预阶段,参与者平均符合 SMP-Pro 灌洗标准 3.83 次(范围 1-20)。平均给予 5.6 剂 LGG。对于至少灌洗一次的参与者,在洗脱时 A 型和 B2 型症状的负担显著改善(均调整 P<.05)。
自行给予 LGG 似乎改善了“具有临床可操作性”(A)和“尿液质量”(B2)的症状负担。未观察到灌洗的参与者有任何变化。这是首次人体临床试验支持了膀胱内 LGG 和 SMP-Pro 治疗尿路症状的进一步研究。